Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.

If American healthcare does not start cleaning house to enable digital innovation, it will pay the price, and inevitably, the patient will as always, be the real victim.

What does a device called the Fluoroscope that measured feet have in common with modern-day DNA medicines? History has a way of repeating

Read more about Jeff Livingston's experiences with digital health and technology in his day to day practice. Part of the Digital Healthcare Equation Series